Life Sciences: Trade Secrets and Data
Life science reporter Adam Houldsworth explains in this article that the pandemic has made it more important than ever to prevent the misappropriation of trade secrets. Pharma and biotech scientists have become more mobile and better able to access valuable information remotely and online (which has probably increased significantly this year). Complex patterns of R&D collaboration between companies and licensing also contribute to these risks, as do growing commercial incentives to find better ways to produce biosimilars. In addition, innovators need to have a strategy in place to protect the confidentiality of regulatory data following the ECJ decision and should consider this early in their R&D process. A clear data strategy on how to commercialise this in new ways is increasingly important – licensing data can save companies time and money and bring new therapies to market faster.